OBJECTIVE: The aim of this study was to evaluate the potential of simultaneously modulated accelerated radiation therapy (SMART) to reduce the incidence of severe acute oesophagitis in the treatment of unresectable locally advanced non-small-cell lung cancer (LANSCLC). METHODS: 21 patients were treated with SMART and concomitant platinum-based chemotherapy. The prescribed doses were limited to 54 Gy at 1.8 Gy per day to the zones of presumed microscopic extent while simultaneously maintaining doses of 66 Gy at 2.2 Gy per day to the macroscopic disease. The whole treatment was delivered over 30 fractions and 6 weeks. Dosimetric parameters of SMART and the standard technique of irradiation [intensity-modulated radiation therapy (IMRT)] were compared. Acute toxicity was prospectively recorded. RESULTS: The highest grade of oesophagitis was 62% (13 patients) grade 1, 33% (7 patients) grade 2 and 5% (1 patient) grade 3. Three (14%) patients experienced acute grade 2 pneumonitis. There was no grade 4 oesophageal or pulmonary toxicity. Doses to the organs at risk were significantly reduced in SMART compared with IMRT [oesophagus: V50Gy, 28.5 Gy vs 39.9 Gy (p = 0.003); V60Gy, 7.1 Gy vs 30.7 Gy (p = 0.003); lung: V20Gy, 27.4 Gy vs 30.1 Gy (p = 0,002); heart: V40Gy, 7.3 Gy vs 10.7 Gy (p = 0.006); spine: Dmax, 42.4 Gy vs 46.4 Gy (p = 0.003)]. With a median follow-up of 18 months (6-33 months), the 1-year local control rate was 70% and the disease-free survival rate was 47%. CONCLUSION: SMART reduces the incidence of severe oesophagitis and improves the whole dosimetric predictors of toxicity for the lung, heart and spine. ADVANCES IN KNOWLEDGE: Our study shows that SMART optimizes the therapeutic ratio in the treatment of LANSCLC, opening a window for dose intensification.
OBJECTIVE: The aim of this study was to evaluate the potential of simultaneously modulated accelerated radiation therapy (SMART) to reduce the incidence of severe acute oesophagitis in the treatment of unresectable locally advanced non-small-cell lung cancer (LANSCLC). METHODS: 21 patients were treated with SMART and concomitant platinum-based chemotherapy. The prescribed doses were limited to 54 Gy at 1.8 Gy per day to the zones of presumed microscopic extent while simultaneously maintaining doses of 66 Gy at 2.2 Gy per day to the macroscopic disease. The whole treatment was delivered over 30 fractions and 6 weeks. Dosimetric parameters of SMART and the standard technique of irradiation [intensity-modulated radiation therapy (IMRT)] were compared. Acute toxicity was prospectively recorded. RESULTS: The highest grade of oesophagitis was 62% (13 patients) grade 1, 33% (7 patients) grade 2 and 5% (1 patient) grade 3. Three (14%) patients experienced acute grade 2 pneumonitis. There was no grade 4 oesophageal or pulmonary toxicity. Doses to the organs at risk were significantly reduced in SMART compared with IMRT [oesophagus: V50Gy, 28.5 Gy vs 39.9 Gy (p = 0.003); V60Gy, 7.1 Gy vs 30.7 Gy (p = 0.003); lung: V20Gy, 27.4 Gy vs 30.1 Gy (p = 0,002); heart: V40Gy, 7.3 Gy vs 10.7 Gy (p = 0.006); spine: Dmax, 42.4 Gy vs 46.4 Gy (p = 0.003)]. With a median follow-up of 18 months (6-33 months), the 1-year local control rate was 70% and the disease-free survival rate was 47%. CONCLUSION: SMART reduces the incidence of severe oesophagitis and improves the whole dosimetric predictors of toxicity for the lung, heart and spine. ADVANCES IN KNOWLEDGE: Our study shows that SMART optimizes the therapeutic ratio in the treatment of LANSCLC, opening a window for dose intensification.
Authors: Zhi-Qin Jiang; Kunyu Yang; Ritsuko Komaki; Xiong Wei; Susan L Tucker; Yan Zhuang; Mary K Martel; Sastray Vedam; Peter Balter; Guangying Zhu; Daniel Gomez; Charles Lu; Radhe Mohan; James D Cox; Zhongxing Liao Journal: Int J Radiat Oncol Biol Phys Date: 2011-11-11 Impact factor: 7.038
Authors: Audrey Mauguen; Cécile Le Péchoux; Michele I Saunders; Steven E Schild; Andrew T Turrisi; Michael Baumann; William T Sause; David Ball; Chandra P Belani; James A Bonner; Aleksander Zajusz; Suzanne E Dahlberg; Matthew Nankivell; Sumithra J Mandrekar; Rebecca Paulus; Katarzyna Behrendt; Rainer Koch; James F Bishop; Stanley Dische; Rodrigo Arriagada; Dirk De Ruysscher; Jean-Pierre Pignon Journal: J Clin Oncol Date: 2012-07-02 Impact factor: 44.544
Authors: José Belderbos; Lon Uitterhoeve; Nico van Zandwijk; Huub Belderbos; Patrick Rodrigus; Paul van de Vaart; Allan Price; Nico van Walree; Catherine Legrand; Sonia Dussenne; Harry Bartelink; Giuseppe Giaccone; Caro Koning Journal: Eur J Cancer Date: 2006-11-03 Impact factor: 9.162
Authors: Margriet Kwint; Wilma Uyterlinde; Jasper Nijkamp; Chun Chen; Josien de Bois; Jan-Jakob Sonke; Michel van den Heuvel; Joost Knegjens; Marcel van Herk; José Belderbos Journal: Int J Radiat Oncol Biol Phys Date: 2012-05-05 Impact factor: 7.038
Authors: Avraham Eisbruch; Jonathan Harris; Adam S Garden; Clifford K S Chao; William Straube; Paul M Harari; Giuseppe Sanguineti; Christopher U Jones; Walter R Bosch; K Kian Ang Journal: Int J Radiat Oncol Biol Phys Date: 2009-06-18 Impact factor: 7.038
Authors: José Marcio Luna; Hann-Hsiang Chao; Russel T Shinohara; Lyle H Ungar; Keith A Cengel; Daniel A Pryma; Chidambaram Chinniah; Abigail T Berman; Sharyn I Katz; Despina Kontos; Charles B Simone; Eric S Diffenderfer Journal: Clin Transl Radiat Oncol Date: 2020-03-24